Murphy S, Rosenthal D S, Weinfeld A, Briere J, Faguet G B, Knospe W H, Landaw S A, Laszlo J, Pisciotta A V, Tartaglia A P
Cancer Treat Rep. 1982 Jul;66(7):1495-500.
Thirty-one patients with essential thrombocythemia were randomized to receive either melphalan or radioactive phosphorus as myelosuppressive therapy. Twenty-seven patients were evaluable for response. Of 13 patients treated with melphalan, 11 had a complete response (platelet count less than 450,000/mm3) at 3 and 6 months. This response rate was significantly better than the response to radioactive phosphorus. The response rates were similar at 12 months. No significant toxicity was observed with either regimen.
